Marksans Pharma Limited

NSE MARKSANS.NS

Marksans Pharma Limited Gross Profit for the year ending March 31, 2024: USD 129.86 M

Marksans Pharma Limited Gross Profit is USD 129.86 M for the year ending March 31, 2024, a 14.67% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Marksans Pharma Limited Gross Profit for the year ending March 31, 2023 was USD 113.25 M, a 17.45% change year over year.
Marksans Pharma Limited Gross Profit for the year ending March 31, 2022 was USD 96.42 M, a -5.84% change year over year.
Marksans Pharma Limited Gross Profit for the year ending March 31, 2021 was USD 102.40 M, a 37.55% change year over year.
Marksans Pharma Limited Gross Profit for the year ending March 31, 2020 was USD 74.44 M, a 10.11% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NSE: MARKSANS.NS

Marksans Pharma Limited

CEO	Mr. Mark B. Saldanha
IPO Date	July 19, 2002
Location	India
Headquarters	Grandeur
Employees	1,141
Sector	Health Care
Industries Pharmaceuticals

Description

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Key trends

Past 5 years